Aplastic anemia is a rare, life-threatening bone marrow disorder characterized by severe low blood counts (pancytopenia) and a markedly hypocellular bone marrow. An Aplastic Anemia Treatment Program aims to restore normal blood cell factory function within the bone marrow. Depending on patient age, physical fitness, and human leukocyte antigen (HLA) donor availability, treatment strategies primary center on either replacing the damaged bone marrow via allogeneic hematopoietic stem cell transplantation (HSCT) or halting immune-mediated marrow destruction using intensive immunosuppressive therapy (IST) combined with bone marrow-stimulating agents.

The treatment protocol follows precise clinical pathways depending on whether the patient receives stem cell transplantation or immunosuppressive therapy. For stem cell transplantation, patients undergo non-myeloablative conditioning using cyclophosphamide, fludarabine, and antithymocyte globulin over 4 to 6 days to clear host immune cells. Healthy donor stem cells are then infused intravenously on Day 0. For non-transplant immunosuppressive therapy, horse antithymocyte globulin is infused intravenously over 4 consecutive days in an inpatient setting, accompanied by prophylactic intravenous steroids to prevent serum sickness. Oral cyclosporine is initiated concurrently and continued for at least 6 months, alongside daily oral eltrombopag for 6 months to directly stimulate stem cell receptors.

Clinical benefits of a structured aplastic anemia treatment program include complete restoration of peripheral blood counts, elimination of transfusion dependency, prevention of fatal infectious or hemorrhagic events, and long-term overall survival rates exceeding 80% to 90% in optimal candidate populations (Killick et al., British Journal of Haematology, 2024). Standardized care protocols also minimize treatment-related mortality and reduce the long-term risk of clonal evolution to secondary myeloid blood disorders.

Initial hematological recovery typically begins within 21 to 28 days following stem cell transplantation or 60 to 90 days following immunosuppressive therapy. Full immune system rebuilding requires 6 to 12 months for transplant recipients and up to 12 to 24 months for patients on oral immunosuppressants. During this time, patients undergo regular blood monitoring, targeted drug level adjustments, prophylactic antimicrobial therapy, and gradual restoration of physical activities.

The program treats all forms of acquired marrow failure, including moderate aplastic anemia (MAA), severe aplastic anemia (SAA), and very severe aplastic anemia (VSAA). It also addresses post-viral aplastic anemia, immune-mediated cytopenias, and refractory marrow failure failing initial conservative management.

Preparation requires a total diagnostic workup including a bone marrow aspiration and core biopsy with cytogenetic analysis to rule out myelodysplastic syndrome. Peripheral blood HLA typing is performed for the patient and siblings. Patients undergo complete organ evaluation including electrocardiography, echocardiography, pulmonary function testing, and renal clearance assessment. Central venous access, such as a double-lumen tunneled Hickman catheter, is surgically placed. Infection screening tests for CMV, EBV, HBV, HCV, HIV, and fungal exposures are completed, and baseline dental clearance is mandatory prior to initiating immunosuppressive or conditioning therapy.

Complications associated with aplastic anemia therapies vary by modality. Immunosuppressive therapy carries risks of acute serum sickness, severe allergic reactions, prolonged neutropenic infection, nephrotoxicity from cyclosporine, hepatic dysfunction from eltrombopag, and long-term clonal evolution to myelodysplastic syndrome or acute myeloid leukemia (10-15% over 10 years). Stem cell transplantation risks include graft failure (5-10%), acute and chronic graft-versus-host disease (10-30%), regimen-related organ toxicity, viral reactivation (CMV, EBV), and secondary malignancies.

The patient journey begins with diagnostic confirmation via bone marrow biopsy and high-resolution HLA tissue typing. During the pre-treatment phase, patients undergo organ function testing, infection screening, and central line placement. Inpatient admission involves either a conditioning chemotherapy protocol prior to stem cell infusion or a multi-day intravenous administration of antithymocyte globulin alongside oral immunosuppressants. Patients remain in specialized HEPA-filtered isolation during the acute neutropenic phase to prevent infection. Following discharge, recovery involves close outpatient monitoring of blood counts, drug levels, and graft status for 12 to 24 months.